Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Infectious Diseases

• Publication date

  2018-03-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jix690PMID 29300980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

  2017cited by this paper
• Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg

  2016cited by this paper
• Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

  2016cited by this paper
• Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients

  2016cited by this paper
• AASLD guidelines for treatment of chronic hepatitis B

  2016cited by this paper
• Hepatitis B virus genotypes and variants.

  2015cited by this paper
• The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B

  2015cited by this paper
• Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

  2015cited by this paper
• Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.

  2015cited by this paper
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

  2015cited by this paper
• Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?

  2015cited by this paper
• Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

  2015cited by this paper
• The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B

  2015cited by this paper
• Perspectives and control of hepatitis B virus infection in Taiwan.

  2015cited by this paper
• Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.

  2015cited by this paper
• Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

  2015cited by this paper
• Influence of cytotoxic T lymphocyte-associated antigen 4 polymorphisms on the outcomes of hepatitis B virus infection.

  2014cited by this paper
• Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

  2014cited by this paper
• Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

  2013cited by this paper
• Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.

  2013cited by this paper
• Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies.

  2013cited by this paper
• HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.

  2013cited by this paper
• Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

  2013cited by this paper
• Hepatitis B viral factors and treatment responses in chronic hepatitis B.

  2013cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

  2012cited by this paper
• Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

  2011cited by this paper
• Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.

  2011cited by this paper
• Strong influence of human leukocyte antigen (HLA)‐DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population

  2011cited by this paper
• Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells

  2011cited by this paper
• Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies

  2011cited by this paper
• +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population.

  2010cited by this paper
• Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B

  2010cited by this paper
• A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians

  2009cited by this paper
• Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

  2008cited by this paper
• Cytotoxic T-Lymphocyte Antigen 4 Gene and Recovery from Hepatitis B Virus Infection

  2004cited by this paper

• The effect of treatment cessation on HBsAg negativity in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)id analogues for more than three years

  2026cites this paper
• Long-term HBsAg clearance, relapse, and safety following tenofovir or entecavir discontinuation in non-cirrhotic, HBeAg-negative chronic hepatitis.

  2026cites this paper
• Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal

  2025cites this paper
• Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis

  2025cites this paper
• Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B

  2025influential citation
• Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

  2025cites this paper
• Switching to entecavir >3 months before the end of tenofovir-based therapy in HBeAg-negative patients may reduce early relapse and hepatitis flare.

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

  2024cites this paper
• Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits

  2024cites this paper
• Assessment of hepatitis B virus relapse in cancer patients receiving chemotherapy with prophylactic nucleos(t)ide analogues: Implications for overall mortality

  2024cites this paper
• Multi-spectral and docking assessments to explore the combination of an antiviral drug, entecavir with bovine serum albumin.

  2024cites this paper
• Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy

  2024influential citation
• Higher hepatitis B core-specific T cell response is associated with a lower risk of clinical relapse after discontinuation of oral antiviral treatment.

  2024cites this paper
• Role of artificial intelligence in the management of chronic hepatitis B infection.

  2024cites this paper
• Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients

  2024influential citation
• Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy.

  2024cites this paper
• When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

  2024cites this paper
• Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen

  2024cites this paper
• Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B

  2023cites this paper
• Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines

  2023cites this paper
• Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

  2023cites this paper
• Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

  2023cites this paper
• Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies

  2023influential citation
• Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.

  2023cites this paper
• Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy

  2023influential citation
• HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide.

  2023cites this paper
• Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up

  2022cites this paper
• Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B.

  2022cites this paper
• A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study

  2022cites this paper
• Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis

  2022cites this paper
• Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection

  2022cites this paper
• Distinct relapse patterns between HBeAg-negative patients stopping tenofovir and entecavir.

  2022cites this paper
• Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

  2022cites this paper
• Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

  2022cites this paper
• Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.

  2021cites this paper
• Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients

  2021cites this paper
• Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure

  2021cites this paper
• APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

  2021cites this paper
• Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

  2021cites this paper
• Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response

  2021cites this paper
• Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

  2021cites this paper
• S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

  2021cites this paper
• Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities

  2021cites this paper
• Clinical management of chronic hepatitis B: A concise overview

  2021cites this paper
• Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

  2021cites this paper
• Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen–Negative Patients: An Asian Perspective

  2020cites this paper
• HBV RNA, Hepatitis B core-related Antigen and Quantitative Hepatitis B surface Antigen- Biomarkers to Predict Outcome of Antiviral Therapy.

  2020cites this paper
• Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

  2020cites this paper
• The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy

  2020cites this paper
• Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat

  2020cites this paper
• High Risk of clinical relapse in HBV-infected patients after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.

  2020cites this paper
• Major Advances in Hepatitis C Treatment but Not Hepatitis B

  2020cites this paper
• Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B

  2020cites this paper
• Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

  2020influential citation
• Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

  2020cites this paper
• Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B

  2020cites this paper
• Serum Alanine Aminotransferase Flares In Chronic Hepatitis B: The Good and The Bad

  2020cites this paper
• Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done.

  2019cites this paper
• Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma

  2019cites this paper
• Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.

  2019cites this paper
• The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg‐negative chronic hepatitis B

  2019cites this paper
• New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection.

  2019cites this paper
• Liver safety assessment in clinical trials of new agents for chronic hepatitis B

  2019cites this paper
• Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

  2019cites this paper
• Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV

  2019cites this paper
• Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

  2019cites this paper
• Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift

  2019cites this paper
• Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection

  2019cites this paper
• Host Genetic Determinants of Hepatitis B Virus Infection

  2019cites this paper
• Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

  2019cites this paper
• Chinese woodchucks with different susceptibility to WHV infection differ in their genetic background exemplified by cytochrome B and MHC-DRB molecules

  2018cites this paper
• New and Old Biomarkers for Diagnosis and Management of Chronic HBV Infection

  2018cites this paper
• Combining hepatitis B core‐related and surface antigens at end of nucleos(t)ide analogue treatment to predict off‐therapy relapse risk

  2018influential citation
• Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

  2018cites this paper
• Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients

  2018cites this paper
• Reply to Liaw.

  2018cites this paper
• EUR Research Information Portal Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

  year unknowncites this paper